Theranostic Research Institute

What Theranostic Research Institute does

Theranostic Research Institute Inc. (株式会社セラノスティック研究所) is a Japan-based private biotech company founded in April 2006 as a spin-off from Nagoya University, headquartered in Midori-ku, Nagoya, Aichi Prefecture. The company develops genetic risk assessment services and personalized medical support products for cardiovascular and lifestyle diseases, including myocardial infarction, coronary artery disease, hypertension, diabetes, and metabolic syndrome, using a population genetics approach built on a database of more than 30,000 cases and 3,500+ genetic polymorphisms analyzed through genome-wide association studies, case-control association analysis, and sibling-pair linkage analysis. The founder, Professor Mitsuhiro Yokota, leads the research program with over four decades of cardiovascular research experience, and the company holds multiple granted patents in Japan, the US, China, Europe, and Korea covering risk diagnosis methods for myocardial infarction, coronary restenosis, coronary spasm, hypertension, metabolic syndrome, and insulin resistance.

The company sells its "Tailor-made Medical Support" (テーラーメード・メディカルサポート) service, marketed under the "Diagment" and "Life Style Passport" brands, directly to medical institutions and healthcare providers in Japan on a quote-based model, supplemented by a secondary corporate occupational health segment. It completed hygiene testing laboratory (衛生検査所) registration in December 2010 and established an ethics review committee in February 2008 to support clinical diagnostic service delivery. Marketing is conducted primarily through academic medical conferences and peer-reviewed publications rather than broad consumer channels, leveraging the founder's academic credentials and research track record in journals such as the New England Journal of Medicine, Nature Genetics, and Circulation.

In January 2015 the company restructured to specialize exclusively in research and development activities, withdrawing from direct product sales, and concurrently relocated its headquarters in February 2015. Initial capitalization was ¥20 million, later increased to ¥30.25 million, and funding to date has come exclusively from Japanese government and quasi-government grants (METI Chubu Bureau, Nagoya City, UFJ Venture Development Fund, NOBUNAGA21, and the SME Infrastructure Development Organization) in 2006-2007, with no subsequent equity investment rounds disclosed. The organization remains small (11-50 employees) and operates solely within Japan despite an international patent footprint.

Name

Theranostic Research Institute

Legal name

株式会社セラノスティック研究所

Website

https://theranos-inst.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Theranostic Research Institute is a Japan-based private biotech company that develops genetic risk assessment services for cardiovascular and lifestyle diseases, selling tailor-made medical support products directly to medical institutions using a 30,000+ case genomic database.

Ownership category

akta.pro rank

Product category

Genetic Diagnostics Services

NAICS

Medical and Diagnostic Laboratories (6215)

SIC

Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Population Genomics & Preventive Precision Health Programs (HLAAANAL)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genetic & Prenatal Testing Laboratories (HLAFAMAH)

Keywords

• Genetic risk assessment
• Genomic diagnostics
• Personalized medicine
• Disease risk prediction
• Preventive healthcare

Headquarters

HQ city

Nagoya

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Genetic Risk Assessment Services: Sale of tailor-made medical support services and risk diagnosis programs to medical institutions and healthcare providers in Japan.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Theranostic Research Institute provides medical-use tailor-made medical support services built around genetic risk assessment for lifestyle diseases, including myocardial infarction, coronary artery disease, cerebral infarction, hypertension, metabolic syndrome, and diabetes. The service leverages a proprietary Japanese-population-specific database of more than 30,000 cases and 3,500+ genetic polymorphisms, applying population-genetics-based GWAS and case-control association analyses. The output is a personalized genetic risk report delivered to healthcare professionals and corporate health programs for use in preventive patient counseling and lifestyle intervention.

Product overview

Theranostic Research Institute offers a suite of genetic risk assessment and personalized healthcare services. The core offering is the genetic risk diagnosis service for lifestyle diseases (myocardial infarction, coronary artery disease, hypertension, metabolic syndrome, diabetes), which analyzes over 3,500 genetic polymorphisms from a database of 30,000+ cases. The company markets these services under the 'Diagment' and 'Life Style Passport' brands for healthcare professionals and individual consumers. The 'Tailor-made Medical Support' product provides medical professionals with tools for delivering personalized prevention strategies based on genetic risk profiles.

Differentiator

Problem solved

Functional benefit

Products and services

• Tailor-made Medical Support Service (テイラーメイド・メディカルサポート)

Quantifiable outcome

• Genetic factors account for 20-40% of lifestyle disease risk, with the remaining 60-80% influenced by lifestyle factors that can be modified through intervention.

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Nagoya University School of MedicinecoreStrategic or Co-development PartnerOriginal research base where founder Professor Mitsuhiro Yokota conducted cardiovascular genomic research, establishing the research foundation for the company's technology.
• Aichi Gakuin University School of DentistrycoreStrategic or Co-development PartnerCurrent academic affiliation of Professor Yokota as Visiting Professor, continuing collaborative genomic research.

Scale indicators3 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• 23andMe: Large US-based direct-to-consumer genetic testing platform offering health risk reports including cardiovascular and metabolic conditions. Comparable in genetic risk assessment product category but operates at vastly larger scale and as a broad portfolio player rather than a specialized cardiovascular/lifestyle disease focus.
• Myriad Genetics: Established US clinical genetics company with a broad hereditary cancer and pharmacogenomic testing portfolio. Comparable as a clinical genetic diagnostics business serving healthcare providers, but operates at significantly larger scale and across a much broader disease portfolio.
• Sema4 (now GeneDx): US clinical genomic testing company offering both reproductive and somatic testing, including population health genomics initiatives. Comparable as a clinical genetic testing service but operates at much larger scale and broader scope.

Direct peers

• Color Genomics: Clinical genetics platform offering hereditary risk and population health genetic testing, including cardiovascular and metabolic risk assessment. Directly comparable in providing genetic risk assessment for chronic disease to healthcare and employer customers.
• Genesis Healthcare: Japanese genetic testing company offering genetic risk assessment services for lifestyle diseases including cardiovascular and metabolic conditions. Most direct domestic comparable given overlap in disease focus, Japanese customer base, and B2B2C distribution model to medical institutions and consumers.
• DeNA Life Science (MYCODE): Operator of the MYCODE consumer and clinical genetic testing service in Japan, including disease risk assessment panels. Directly comparable in target market (Japanese consumers and medical institutions) and product category (genetic risk testing for lifestyle and complex diseases).

Emerging players

• Genetic Technologies: Australia-based company focused on polygenic risk scores for cancer and cardiovascular disease risk assessment. Comparable in the niche of polygenic/genetic risk scoring for complex disease prevention, though focused on different therapeutic areas.
• Helix: US-based population genomics and clinical genetic testing platform partnering with health systems and employers. Comparable in applying population-scale genetic data to preventive health use cases, though operating at much larger scale and with broader product scope.
• CytoSport / Tauns Laboratories (Cellgenics): Japan-based clinical genetic testing services and laboratory partner. Comparable as a domestic clinical genetic testing operator; smaller and more service-oriented but overlaps in customer base (Japanese medical institutions seeking genetic testing infrastructure).

Regional players

• Eurofins Genomic Japan / GenePlanet: European direct-to-consumer and clinical genetic testing provider with polygenic risk score offerings for cardiovascular and lifestyle disease. Comparable in product category (lifestyle disease genetic risk testing) but primarily serves European rather than Japanese customers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Theranostic Research Institute